1. Home
  2. LH vs NTRA Comparison

LH vs NTRA Comparison

Compare LH & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Laboratory Corporation of America Holdings

LH

Laboratory Corporation of America Holdings

HOLD

Current Price

$258.93

Market Cap

21.4B

Sector

Health Care

ML Signal

HOLD

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$244.06

Market Cap

27.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LH
NTRA
Founded
1971
2003
Country
United States
United States
Employees
70000
N/A
Industry
Medical Specialities
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.4B
27.0B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
LH
NTRA
Price
$258.93
$244.06
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
16
Target Price
$299.00
$227.69
AVG Volume (30 Days)
952.3K
1.7M
Earning Date
10-28-2025
11-06-2025
Dividend Yield
1.11%
N/A
EPS Growth
98.36
N/A
EPS
10.19
N/A
Revenue
$13,765,300,000.00
$2,116,676,000.00
Revenue This Year
$10.82
$32.77
Revenue Next Year
$4.44
$16.51
P/E Ratio
$25.37
N/A
Revenue Growth
8.28
38.17
52 Week Low
$209.38
$125.38
52 Week High
$293.72
$245.59

Technical Indicators

Market Signals
Indicator
LH
NTRA
Relative Strength Index (RSI) 41.12 80.03
Support Level $264.66 $233.67
Resistance Level $272.82 $240.18
Average True Range (ATR) 5.02 7.39
MACD -0.05 0.68
Stochastic Oscillator 4.62 97.49

Price Performance

Historical Comparison
LH
NTRA

About LH Laboratory Corporation of America Holdings

Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: